Beneficial Effects of Prebiotic Saccharomyces cerevisiae Mannan on Allergic Asthma Mouse Models.
D Betty LewChristie F MichaelTracie OverbeckW Scout RobinsonErin L RohmanJeffrey M LehmanJennifer K PatelBrandi EisemanKim S LeMessurierAmali E SamarasingheM Waleed GaberPublished in: Journal of immunology research (2017)
One of the unmet needs for asthma management is a new therapeutic agent with both anti-inflammatory and anti-smooth muscle (ASM) remodeling effects. The mannose receptor (MR) family plays an important role in allergen uptake and processing of major allergens Der p 1 and Fel d 1. We have previously reported that ASM cells express a mannose receptor (ASM-MR) and that mannan derived from Saccharomyces cerevisiae (SC-MN) inhibits mannosyl-rich lysosomal hydrolase-induced bovine ASM cell proliferation. Using a humanized transgenic mouse strain (huASM-MRC2) expressing the human MRC2 receptor in a SM tissue-specific manner, we have demonstrated that ASM hyperplasia/hypertrophy can occur as early as 15 days after allergen challenge in this mouse model and this phenomenon is preventable with SC-MN treatment. This proof-of-concept study would facilitate future development of a potential asthma therapeutic agent with dual function of anti-inflammatory and anti-smooth muscle remodeling effects.
Keyphrases
- smooth muscle
- saccharomyces cerevisiae
- allergic rhinitis
- mouse model
- anti inflammatory
- chronic obstructive pulmonary disease
- lung function
- cell proliferation
- endothelial cells
- magnetic resonance
- contrast enhanced
- induced apoptosis
- cell cycle arrest
- emergency department
- current status
- cell death
- binding protein
- monoclonal antibody
- pi k akt
- replacement therapy
- stress induced